Innovation World Large Caps by AMG
Fund size USD 21.6m
Past performance is not a reliable indicator of future performance. Please note that the aforementioned performance is shown in the fund currency USD (US Dollar) and not Euro and therefore currency influences in investment currencies other than the fund currency are not taken into account in the performance shown.
The equity fund invests globally («developed markets» only) in listed companies with above-average innovation efficiency. The fund invests across all sectors, with the exception of «utilities» and «financials». The investment process consists of a two-step procedure. As a first step, the innovation efficiency of the companies within the investment universe is measured and compared using a scientifically based quantitative method. In the subsequent step, the portfolio is constructed by selecting around 30 stocks based on our own proprietary fundamental analysis.
Portfolio Management
- Patrick Hofer
- Portfolio Management
Client Relationship Management - patrick.hofer[at]serafin-am.com
- +41 (41) 726 71 76
Portfolio Management
- Patrick Hofer
- Portfolio Management
Client Relationship Management
Serafin Innovation Hub
- Dr. Julian Kauffeldt
- Head of Innovation Investment Products
Serafin Innovation Hub
- Dr. Niklas Bayrle
- Investment Specialist
Serafin Innovation Hub - niklas.bayrle[at]serafin-am.com
- +41 (41) 726 71 71
Serafin Innovation Hub
- Dr. Julian Kauffeldt
- Head of Innovation Investment Products
Serafin Innovation Hub
- Dr. Niklas Bayrle
- Investment Specialist
Serafin Innovation Hub
Learn more about the ESG fund classification
Sustainability / ESG
Brief profile:
Innovation World Large Caps
Invest in innovation champions worldwide and rely on profitable innovation leaders!
Publications
TWO PAGER | INNOVATION
Breakdown by sectors
Breakdown by currencies
Breakdown by countries
Comment March 2024
The Innovation World Large Caps Fund performed well in March but was not quite able to keep pace with the benchmark index.
The US company Vertex Pharmaceuticals Inc. is a biopharmaceutical company specializing in the research, development, and marketing of micromolecular drugs, particularly for the treatment of cancer, viral, inflammatory, and autoimmune diseases. The innovation focus is on the use of new scientific technologies such as gene editing. It has the potential to revolutionize the way genetic diseases are treated. Vertex has a solid pipeline of drug candidates in various stages of clinical development. The strong research and development pipeline demonstrates the company's innovative ability to identify and develop new therapies. To expand into other therapeutic areas, Vertex is leveraging its scientific expertise and success in CF (cystic fibrosis, a rare, life-threatening genetic disease). This could further increase the company's potential for innovation and growth.
ESG implementation:
We take ESG aspects into account in the financial analysis and investment decision-making process, applying a combination of exclusion criteria and ESG integration approach in the investment process. The abbreviation ESG stands for "Environmental - Social - Governance".
For the analysis within the sustainability approach, we rely on data from selected third-party providers and, if necessary, on our own analyses. The analysts and portfolio management teams are responsible for both the financial analysis and the ESG analysis. In this way, we ensure that the assessment and implementation are carried out on a recurring basis by the decision-makers in the respective fund as part of a comprehensive and integrated investment process.
In our investment process, we do not per se exclude investments in companies with weaker ESG ratings: Companies that address the issue of sustainability convincingly and consistently can be interesting portfolio companies.
Latest ESG reporting:
- Classification with regard to U.N. Global Compact Ten Principles:
All portfolio companies in the fund comply with the U.N. Global Compact Ten Principles. - Current portfolio structure using the ESG Risk Rating (by Sustainalytics):
The above fund is a financial product within the meaning of Article 8 of Regulation (EU) 2019/2088 (Disclosure Regulation).
For more information on the fulfillment of environmental and/or social characteristics, please refer to the fund prospectus.
Sustainability-related disclosures
| Domicile of fund | Luxembourg |
|---|---|
| Legal form | SICAV (UCITS V) |
| Investment universe | Global (Developed Markets) |
| Investment manager | Serafin Asset Management Ltd, Zug |
| Management company | VP Fund Solutions (Luxembourg) SA, Lux |
| Custodian bank | VP Bank (Luxembourg) SA, Lux |
| Launch date | 17.12.2019 |
| Recommended investment horizon | 5 years |
| Reference currency | USD |
| ISIN / Bloomberg-Ticker (respective share class) | A USD: LU2084863575 / GIIWLCA LX B CHF-hedged: LU2084868962 / GIIWLCB LX C USD: LU2084869424 / GIIWLCC LX E EUR-hedged: LU2127862683 / GLWLAEE LX G EUR-hedged: LU2127862840 / GLWLAGE LX |
| Distributions | accumulating |
| Subscription and redemption | daily (cut-off 12.00 CET) |
| Tax transparency | CH, AT |
| Tax status Germany | Equity fund pursuant to InvStG with partial exemption |
| Registered for public distribution | CH, DE, AT, LUX, UK |
Gebührenstruktur
| Subscription and redemption fee | none |
|---|---|
| Management fee p.a. | Tranche A USD: 1.04% Tranche B CHF-hedged: 1.04% Tranche C USD: 1.54% Tranche E EUR-hedged: 1.04% Tranche G EUR-hedged: 1.54% |
| MiFID fee for third party research p.a. | 0.04% |
| Total expense ratio p.a. (per 31.03.2023; TER) | Tranche A USD: 1.56% Tranche B CHF-hedged: 1.55% Tranche C USD: 2.05% Tranche E EUR-hedged: 1.55% Tranche G EUR-hedged: 2.05% |
| Duration | Fund | MSCI World ETF |
|---|---|---|
| 1 month | -4.5% | -3.9% |
| 3 months | 0.4% | 2.9% |
| 12 months | 9.5% | 18.4% |
| 3 years p.a. | 3.1% | 5.7% |
| since inception p.a. | 7.1% | 10.1% |
| Year | ||
| 2024 | 0.1% | 4.8% |
| 2023 | 19.2% | 24.2% |
| 2022 | -15.9% | -18.8% |
| 2021 | 15.7% | 22.4% |
| 2020 | 16.0% | 16.3% |
| since inception | 34.8% | 51.5% |
Risk ratios (rolling over the last 3 years)
| Volatility (p.a.) | 17.9% |
|---|---|
| Sharpe ratio (2.74% Risk free rate) | 0.02 |
| Beta (vs. MSCI World ETF) | 0.95 |
The gross performance takes into account the costs incurred at fund level (e.g. management fee) without including the costs incurred at investor level (e.g. front-end load and custody fees). The net performance also takes into account an initial sales charge of 0.00% in the first period under review.